{"product_id":"sdgr-vrio-analysis","title":"Schrödinger, Inc. (SDGR): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eUnlocking the secrets to Schrödinger, Inc. (SDGR)'s market staying power starts here. This concise VRIO analysis cuts straight to the chase, revealing precisely which of its assets are Valuable, Rare, Inimitable, and Organized for enduring competitive advantage. Scroll down to see the definitive breakdown and what it means for their future success.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eSchrödinger, Inc. (SDGR) - VRIO Analysis: 1. Physics-Based Computational Platform\n\u003c\/h2\u003e\n\u003cp\u003eYou're looking at a core asset that defines Schrödinger, Inc.'s market position: their physics-based computational platform. This technology is the engine driving their high-value software segment, and understanding its VRIO profile tells us exactly where their durable edge lies.\u003c\/p\u003e\n\n\u003ch\u003ePhysics-Based Computational Platform\u003c\/h\u003e\n\u003cp\u003eThe platform’s \u003cstrong\u003eValue\u003c\/strong\u003e is clear: it lets clients accurately predict molecular properties, which translates directly into cutting R\u0026amp;D time and cost. For the 2025 fiscal year, management has guided for software revenue growth in the range of \u003cstrong\u003e8%\u003c\/strong\u003e to \u003cstrong\u003e13%\u003c\/strong\u003e, showing continued, albeit moderated, demand for this core offering.\u003c\/p\u003e\n\u003cp\u003eIt’s \u003cstrong\u003eRare\u003c\/strong\u003e because it’s not just another AI\/ML tool; it’s a specific, powerful blend of deep physics-based methods with machine learning, creating what is effectively a unique Digital Chemistry Laboratory. This technological depth is evidenced by the fact that the platform is licensed by \u003cstrong\u003e19 of the top 20\u003c\/strong\u003e global pharmaceutical companies.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability\u003c\/strong\u003e is high, which is good for Schrödinger, Inc. Replicating this isn't a matter of hiring a few data scientists; it requires replicating over \u003cstrong\u003e30 years\u003c\/strong\u003e of cumulative R\u0026amp;D investment and deep scientific expertise to match the core algorithms. The cost to imitate is massive, likely involving R\u0026amp;D spending in the hundreds of millions over a decade, similar to their reported Q3 2025 R\u0026amp;D expense of \u003cstrong\u003e$42.8 million\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003eThe \u003cstrong\u003eOrganization\u003c\/strong\u003e around this asset is strong. The platform is the foundation for both the recurring software licensing revenue - which hit \u003cstrong\u003e$40.9 million\u003c\/strong\u003e in Q3 2025 - and the high-upside drug discovery collaboration revenue. The company is organizing itself to maximize this by strategically pivoting away from independent clinical development to focus on partnership-driven value capture.\u003c\/p\u003e\n\u003cp\u003eThis combination results in a \u003cstrong\u003eSustained Competitive Advantage\u003c\/strong\u003e. The technology is scientifically complex, deeply embedded in major pharma workflows, and constantly being advanced, making it difficult for rivals to catch up or substitute effectively.\u003c\/p\u003e\n\u003cp\u003eHere’s the quick math on the platform’s dual role:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\/Range (2025 Fiscal Year Data)\u003c\/th\u003e\n\u003cth\u003eSource of Advantage\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSoftware Revenue Growth Guidance\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e8%\u003c\/strong\u003e to \u003cstrong\u003e13%\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eDemand \u0026amp; Stickiness\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D Investment (Q3 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$42.8 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eCost of Imitation\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTop Pharma Clients\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e19 of 20\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eRarity \u0026amp; Validation\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePlatform R\u0026amp;D History\u003c\/td\u003e\n\u003ctd\u003eOver \u003cstrong\u003e30 years\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eImitability Barrier\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eWhat this estimate hides is the specific impact of the new predictive toxicology solution, which is expected to contribute significantly later, but its initial margin impact is already visible in the software gross margin fluctuation.\u003c\/p\u003e\n\u003cp\u003eTo translate this into action, you should focus on:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eMonitor software renewal rates closely.\u003c\/li\u003e\n\u003cli\u003eAssess the integration depth of the platform at key clients.\u003c\/li\u003e\n\u003cli\u003eTrack R\u0026amp;D spend efficiency versus competitor disclosures.\u003c\/li\u003e\n\u003cli\u003eEvaluate partnership deal structures for royalty upside.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eFinance: draft 13-week cash view by Friday.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eSchrödinger, Inc. (SDGR) - VRIO Analysis: 2. Top-Tier Pharmaceutical Customer Base\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Provides stable, high-margin recurring revenue and acts as a powerful validation signal for new clients.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eCustomer retention rate among customers with an ACV of at least \u003cstrong\u003e$500,000\u003c\/strong\u003e was \u003cstrong\u003e100%\u003c\/strong\u003e in 2024.\u003c\/li\u003e\n\u003cli\u003eSoftware gross margin for the full year 2024 was \u003cstrong\u003e80%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe ACV of Top 10 customers increased \u003cstrong\u003e43%\u003c\/strong\u003e to \u003cstrong\u003e$73.1 million\u003c\/strong\u003e in 2024.\u003c\/li\u003e\n\u003cli\u003eFull-year 2024 Software Revenue was \u003cstrong\u003e$180.4 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate; many large pharma companies have internal capabilities, but Schrödinger’s near-universal adoption is notable.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eIn 2024, \u003cstrong\u003e19\u003c\/strong\u003e of the top 20 pharmaceutical companies were licensed users.\u003c\/li\u003e\n\u003cli\u003eThese top 20 pharma companies accounted for \u003cstrong\u003e41%\u003c\/strong\u003e of software revenue in 2024.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Moderate; competitors can target the same clients, but replacing Schrödinger requires a proven, superior technology.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High; strong customer retention rates indicate the company is organized to service and maintain these large contracts.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eNumber of customers with ACV $\\ge$ \u003cstrong\u003e$500,000\u003c\/strong\u003e increased from \u003cstrong\u003e54\u003c\/strong\u003e in 2023 to \u003cstrong\u003e61\u003c\/strong\u003e in 2024.\u003c\/li\u003e\n\u003cli\u003eNumber of customers with ACV $\\ge$ \u003cstrong\u003e$1 million\u003c\/strong\u003e grew from \u003cstrong\u003e27\u003c\/strong\u003e in 2023 to \u003cstrong\u003e31\u003c\/strong\u003e in 2024.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary; while strong now, a major competitor breakthrough could erode this base.\u003c\/p\u003e\n\n\u003ch3\u003eKey Customer Metrics (2023 vs. 2024)\u003c\/h3\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2023 Data\u003c\/th\u003e\n\u003cth\u003e2024 Data\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCustomers with ACV $\\ge$ $500,000\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e54\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e61\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCustomers with ACV $\\ge$ $1 Million\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e27\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e31\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCustomers with ACV $\\ge$ $5 Million\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e4\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e8\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTop 10 Customers ACV\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$51.0 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$73.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCustomer Retention Rate (ACV $\\ge$ $500k)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e98%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e100%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSoftware Revenue (Full Year)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$159.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$180.4 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cbr\u003e\u003ch2\u003eSchrödinger, Inc. (SDGR) - VRIO Analysis: 3. Dual Revenue Model Structure\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Balances predictable, high-margin software licensing (projected 8% to 13% growth) with high-upside, milestone-driven drug discovery revenue (projected $49 million to $52 million for 2025). The software gross margin for the full year 2025 is expected to range from 73% to 75%.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eRevenue Stream\u003c\/th\u003e\n\u003cth\u003eLatest Quarterly Performance (Q3 2025)\u003c\/th\u003e\n\u003cth\u003eFull Year 2025 Guidance Metric\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSoftware Revenue\u003c\/td\u003e\n\u003ctd\u003e$40.9 million\u003c\/td\u003e\n\u003ctd\u003eGrowth of 8% to 13%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDrug Discovery Revenue\u003c\/td\u003e\n\u003ctd\u003e$13.5 million\u003c\/td\u003e\n\u003ctd\u003eRange of $49 million to $52 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate; many software firms do not have a credible, in-house drug discovery arm to drive collaboration revenue. The company secured a $150 million upfront payment from Novartis in Q1 2025 related to a collaboration.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e High; requires both world-class software engineering and successful preclinical\/clinical program management. The company has three proprietary Phase 1 clinical programs: SGR-1505, SGR-2921, and SGR-3515, with initial data expected for SGR-2921 and SGR-3515 in Q4 2025.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High; the company successfully pivoted to focus on partnerships for its clinical pipeline in 2025. This pivot was accompanied by a $30 million expense reduction plan. The company maintained $401 million in cash and marketable securities as of September 30, 2025.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained; the synergy between the two streams reinforces the platform’s value proposition. Key operational metrics supporting this include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eSoftware revenue for Q3 2025 grew 28% year-over-year to $40.9 million.\u003c\/li\u003e\n\u003cli\u003eDrug discovery revenue for Q3 2025 surged 295% year-over-year to $13.5 million.\u003c\/li\u003e\n\u003cli\u003eTotal revenue for Q3 2025 was $54.3 million, a 54% increase year-over-year.\u003c\/li\u003e\n\u003cli\u003eDeferred revenue reached $174.7 million as of September 30, 2025, up from $47 million in Q3 2024.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eSchrödinger, Inc. (SDGR) - VRIO Analysis: 4. High-Value Strategic Collaboration Framework\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue\u003c\/strong\u003e\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eCollaboration Partner\u003c\/td\u003e\n\u003ctd\u003eUpfront Cash Infusion\u003c\/td\u003e\n\u003ctd\u003eTotal Potential Milestones (Excl. Royalties)\u003c\/td\u003e\n\u003ctd\u003eRoyalty Structure\u003c\/td\u003e\n\u003ctd\u003eSoftware Agreement Term\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNovartis (Announced Nov 2024)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$150 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eUp to \u003cstrong\u003e$2.3 billion\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eTiered \u003cstrong\u003emid single-digit to low double-digit\u003c\/strong\u003e on net sales\u003c\/td\u003e\n\u003ctd\u003eExpanded \u003cstrong\u003ethree-year\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBristol Myers Squibb (Mentioned Context)\u003c\/td\u003e\n\u003ctd\u003eN\/A (Upfront not specified)\u003c\/td\u003e\n\u003ctd\u003eUp to \u003cstrong\u003e$2.7 billion\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003ePlus \u003cstrong\u003eroyalties\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe Novartis upfront payment of \u003cstrong\u003e$150 million\u003c\/strong\u003e was expected in Q1 2025.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe structure is not common for pure software vendors, evidenced by:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eTotal collaborators since 2018 increased to \u003cstrong\u003e19\u003c\/strong\u003e as of February 26, 2025.\u003c\/li\u003e\n\u003cli\u003eThe company ended 2024 with \u003cstrong\u003e13\u003c\/strong\u003e ongoing programs eligible for royalties.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eImitability\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eJustification for large payouts is supported by historical and projected figures:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eNovartis potential milestones: Up to \u003cstrong\u003e$892 million\u003c\/strong\u003e (R\u0026amp;D\/Regulatory) + Up to \u003cstrong\u003e$1.38 billion\u003c\/strong\u003e (Commercial).\u003c\/li\u003e\n\u003cli\u003eA prior deal with Nimbus Therapeutics resulted in a sale worth up to \u003cstrong\u003e$1.2 billion\u003c\/strong\u003e (2016).\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eManagement of complex agreements is reflected in financial reporting:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e2025 Drug Discovery revenue guidance (Feb 2025): \u003cstrong\u003e$45 million to $50 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003e2025 projected Drug Discovery revenue (Nov 2025 update): \u003cstrong\u003e$49 million to $52 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eQ1 2025 Drug Discovery revenue: \u003cstrong\u003e$10.735 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAdvantage is sustained by closing new, large-scale deals, as shown by recent revenue figures:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e2024 Software Revenue: \u003cstrong\u003e$180.4 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eQ1 2025 Software Revenue: \u003cstrong\u003e$48.816 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003e2025 Software revenue growth expected to range from \u003cstrong\u003e10% to 15%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eSchrödinger, Inc. (SDGR) - VRIO Analysis: 5. Proprietary Enterprise Informatics Solutions\n\u003c\/h2\u003e\n\u003ch3\u003eValue\u003c\/h3\u003e\n\u003cp\u003eIncreases platform stickiness by facilitating team collaboration and data management across R\u0026amp;D departments. The launch of LiveDesign Biologics addresses the growing biologics market. \u003cstrong\u003eLiveDesign\u003c\/strong\u003e serves as a flexible, cloud-native working environment for small and large molecule research, including biologics discovery workflows.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003ePeriod\/Context\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSoftware Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$159.1 Million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFull Year 2023\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSoftware Revenue Growth\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e13.3%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFull Year 2024 over 2023\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSoftware Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$48.8 Million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ1 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSoftware Revenue Growth\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e46%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ1 2025 Year-over-Year\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSoftware Gross Margin\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e81%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFull Year 2023\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003ch3\u003eRarity\u003c\/h3\u003e\n\u003cp\u003eModerate; while informatics tools exist, Schrödinger’s is specifically integrated with its physics-based modeling engine. The integration allows for features such as:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eOne-click access to powerful molecular and thin film simulations and machine learning workflows.\u003c\/li\u003e\n\u003cli\u003eAccurate prediction of optoelectronic properties of materials with just one click using automated workflows.\u003c\/li\u003e\n\u003cli\u003eIn one materials science case study, LiveDesign facilitated high-throughput screening of a library of \u003cstrong\u003e9,000 molecules\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eImitability\u003c\/h3\u003e\n\u003cp\u003eModerate; requires significant investment in software development beyond core simulation science. The platform's integration depth and proprietary scientific algorithms present a barrier to replication. A forecasted Food and Drug Administration (FDA) procurement for \u003cstrong\u003eLiveDesign\u003c\/strong\u003e was valued up to \u003cstrong\u003e$250,000\u003c\/strong\u003e.\u003c\/p\u003e\n\u003ch3\u003eOrganization\u003c\/h3\u003e\n\u003cp\u003eHigh; these tools are key to driving software adoption and increasing the value of existing licenses. The platform supports centralized collaboration and decision-making, allowing teams to interactively revise design strategies. Hosted revenue constituted \u003cstrong\u003e28%\u003c\/strong\u003e of total software revenue in Q2 2025, up from \u003cstrong\u003e23%\u003c\/strong\u003e in Q3 2023, indicating a transition to cloud-native adoption.\u003c\/p\u003e\n\u003ch3\u003eCompetitive Advantage\u003c\/h3\u003e\n\u003cp\u003eTemporary; other informatics platforms can integrate similar features over time. The competitive advantage is maintained through continuous scientific advancement of the underlying physics-based modeling engine and the expansion of modality support, such as \u003cstrong\u003eLiveDesign for Biologics\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eSchrödinger, Inc. (SDGR) - VRIO Analysis: 6. Internal, Computationally-Derived Clinical Pipeline\n\u003c\/h2\u003e\n\u003ch3\u003eValue\u003c\/h3\u003e\n\u003cp\u003ePotential for massive royalty\/milestone payments upon successful clinical validation of platform-derived candidates. The company is advancing SGR-1505 and SGR-3515 through Phase 1 studies. \u003cstrong\u003e$150 million\u003c\/strong\u003e upfront payment received from Novartis in January 2025 from a collaboration. Drug Discovery Revenue guidance for Full Year 2025 is now $49 million to $52 million.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eTarget\/Mechanism\u003c\/th\u003e\n\u003cth\u003ePhase 1 Initiation\/IND Clearance\u003c\/th\u003e\n\u003cth\u003eKey Data Readout (Reported\/Expected)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSGR-1505\u003c\/td\u003e\n\u003ctd\u003eMALT1 inhibitor\u003c\/td\u003e\n\u003ctd\u003eEnrollment ongoing (Q1 2024)\u003c\/td\u003e\n\u003ctd\u003eInitial data presented in June 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSGR-3515\u003c\/td\u003e\n\u003ctd\u003eWee1\/Myt1 inhibitor\u003c\/td\u003e\n\u003ctd\u003eIND cleared Q1 2024; Phase 1 initiated Q3 2024\u003c\/td\u003e\n\u003ctd\u003eInitial clinical data expected Q4 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003ch3\u003eRarity\u003c\/h3\u003e\n\u003cp\u003eModerate; the asset class is rare as many software companies avoid direct clinical trial risk. Drug Discovery Revenue for Q3 2025 was \u003cstrong\u003e$13.5 million\u003c\/strong\u003e.\u003c\/p\u003e\n\u003ch3\u003eImitability\u003c\/h3\u003e\n\u003cp\u003eHigh; requires deep internal scientific and clinical development expertise built over more than \u003cstrong\u003e30 years\u003c\/strong\u003e of R\u0026amp;D investment.\u003c\/p\u003e\n\u003ch3\u003eOrganization\u003c\/h3\u003e\n\u003cp\u003eModerate; the company is strategically reducing independent clinical spend to focus on partnering these assets. Research \u0026amp; Development (R\u0026amp;D) Expenses for Q2 2025 were \u003cstrong\u003e$43.1 million\u003c\/strong\u003e, a greater than \u003cstrong\u003e15% decrease\u003c\/strong\u003e from $50.8 million in Q2 2024.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003eStrategic Shift: Beyond planned Phase 1 completion for SGR-1505 and SGR-3515, the company does not intend to advance discovery programs into the clinic independently.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eExpense Reduction: Announced expense-reduction measures expected to result in savings of approximately \u003cstrong\u003e$70 million\u003c\/strong\u003e.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eCompetitive Advantage\u003c\/h3\u003e\n\u003cp\u003eSustained; successful clinical readouts validate the entire business model, which includes Software Revenue growth expected between \u003cstrong\u003e8% to 13%\u003c\/strong\u003e for Full Year 2025.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eSchrödinger, Inc. (SDGR) - VRIO Analysis: 7. Strong Balance Sheet and Cash Position\n\u003c\/h2\u003e\n\n\u003ch\u003e\u003ch\u003eValue: Provides a buffer against macroeconomic uncertainty and funds strategic R\u0026amp;D without immediate dilution.\u003c\/h\u003e\n\u003cp\u003eCash, cash equivalents, restricted cash and marketable securities stood at \u003cstrong\u003e$401.0 million\u003c\/strong\u003e as of September 30, 2025. This compares to \u003cstrong\u003e$367.5 million\u003c\/strong\u003e at December 31, 2024.\u003c\/p\u003e\n\n\u003ch\u003e\u003ch\u003eRarity: Low; many biotech\/software firms operate with tighter cash positions.\u003c\/h\u003e\n\u003cp\u003eThe cash position of \u003cstrong\u003e$401.0 million\u003c\/strong\u003e as of September 30, 2025, provides a significant liquidity buffer.\u003c\/p\u003e\n\n\u003ch\u003e\u003ch\u003eImitability: Low; this is a result of past financing and operational management, not a core repeatable process.\u003c\/h\u003e\n\u003cp\u003eThe current cash level is primarily a function of historical financing activities and strategic capital management decisions. The ability to generate significant cash from operations or drug discovery milestones is not a consistent, repeatable process in the short term. Drug discovery revenue for Q3 2025 was \u003cstrong\u003e$13.5 million\u003c\/strong\u003e, compared to \u003cstrong\u003e$3.4 million\u003c\/strong\u003e in Q3 2024, driven by milestone recognition.\u003c\/p\u003e\n\n\u003ch\u003e\u003ch\u003eOrganization: High; management is focused on lowering operating expenses, which improved cash usage in 2025.\u003c\/h\u003e\n\u003cp\u003eManagement actions focused on expense reduction are evident in the quarterly figures. Total operating expenses for Q3 2025 were \u003cstrong\u003e$74 million\u003c\/strong\u003e, a decrease of \u003cstrong\u003e14%\u003c\/strong\u003e compared to Q3 2024. These actions are expected to result in savings of approximately \u003cstrong\u003e$70 million\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eR\u0026amp;D expenses for Q3 2025 were \u003cstrong\u003e$42.8 million\u003c\/strong\u003e, a \u003cstrong\u003e16%\u003c\/strong\u003e decrease from \u003cstrong\u003e$51 million\u003c\/strong\u003e in Q3 2024.\u003c\/li\u003e\n\u003cli\u003eSales and marketing expense was \u003cstrong\u003e$9.5 million\u003c\/strong\u003e, an \u003cstrong\u003e8%\u003c\/strong\u003e decrease compared to Q3 2024.\u003c\/li\u003e\n\u003cli\u003eGeneral and Administrative (G\u0026amp;A) expense decreased \u003cstrong\u003e13%\u003c\/strong\u003e to \u003cstrong\u003e$21.7 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinancial Metric\u003c\/td\u003e\n\u003ctd\u003eQ3 2024 Period Data\u003c\/td\u003e\n\u003ctd\u003eQ3 2025 Period Data\u003c\/td\u003e\n\u003ctd\u003eChange\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash \u0026amp; Securities (Period End)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$367.5 million\u003c\/strong\u003e (Dec 31, 2024)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$401.0 million\u003c\/strong\u003e (Sep 30, 2025)\u003c\/td\u003e\n\u003ctd\u003eIncrease\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Operating Expenses\u003c\/td\u003e\n\u003ctd\u003eImplied $\\approx$ \u003cstrong\u003e$86.05 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$74 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e-14%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D Expenses\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$51 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$42.8 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e-16%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eG\u0026amp;A Expense\u003c\/td\u003e\n\u003ctd\u003eImplied $\\approx$ \u003cstrong\u003e$24.94 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$21.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e-13%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eExpected Annualized Savings from Measures\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$70 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003ch\u003e\u003ch\u003eCompetitive Advantage: Temporary; cash reserves deplete over time if not replenished by operations.\u003c\/h\u003e\n\u003cp\u003eThe competitive advantage derived from cash reserves is subject to the burn rate, as evidenced by the GAAP net loss of \u003cstrong\u003e$32.8 million\u003c\/strong\u003e for Q3 2025. Software revenue for Q3 2025 was \u003cstrong\u003e$40.9 million\u003c\/strong\u003e, an increase of \u003cstrong\u003e28%\u003c\/strong\u003e compared to Q3 2024.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eSchrödinger, Inc. (SDGR) - VRIO Analysis: 8. Advanced AI\/ML Integration with Physics\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Allows the platform to move beyond pure simulation to faster, more targeted hypothesis generation, a key strategic priority for \u003cstrong\u003e2025\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate; the combination of first-principles physics and modern machine learning is a specialized niche.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e High; requires specialized talent in both computational physics and advanced data science.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High; this integration is central to their platform enhancement roadmap.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained; continuous scientific advancement in this area creates a moving target for rivals.\u003c\/p\u003e\n\u003cp\u003e\n\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003eContext\/Period\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePredictive Toxicology Targets (Initial)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e50-plus\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003ePlanned for \u003cstrong\u003e2025\u003c\/strong\u003e Initiative\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePredictive Toxicology Targets (Scale Goal)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e100-plus\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003ePlanned for \u003cstrong\u003e2026\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePredictive Toxicology Grant Funding\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$19.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eBill \u0026amp; Melinda Gates Foundation\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePredictive Tox Revenue Contribution\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$4.9 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ4-2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D Investment Basis\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e30+ years\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003ePlatform foundation\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Software ACV\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$190.8 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of December 31, 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSoftware Revenue YoY Growth\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e46%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ1 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe predictive toxicology initiative integrates physics and ML to deliver highly accurate predictions of off-target binding.\u003c\/li\u003e\n\u003cli\u003eThe company expects to present initial Phase 1 data from its three lead proprietary therapeutic programs in \u003cstrong\u003e2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eSoftware revenue for Q3 2025 was \u003cstrong\u003e$40.9 million\u003c\/strong\u003e, a \u003cstrong\u003e28%\u003c\/strong\u003e growth year-over-year.\u003c\/li\u003e\n\u003cli\u003eSoftware gross margin is expected to range from \u003cstrong\u003e74%\u003c\/strong\u003e to \u003cstrong\u003e75%\u003c\/strong\u003e for the fiscal year ending December 31, \u003cstrong\u003e2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe global AI in the drug discovery market is projected to grow at a CAGR of \u003cstrong\u003e29.7%\u003c\/strong\u003e from \u003cstrong\u003e2024\u003c\/strong\u003e to \u003cstrong\u003e2030\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eFunding for AI-driven drug discovery startups exceeded \u003cstrong\u003e$3 billion\u003c\/strong\u003e in \u003cstrong\u003e2024\u003c\/strong\u003e (as of 12\/09\/2024), up \u003cstrong\u003e43%\u003c\/strong\u003e from the \u003cstrong\u003e2023\u003c\/strong\u003e level.\u003c\/li\u003e\n\u003cli\u003eAn expense reduction program is anticipated to save \u003cstrong\u003e$30 million\u003c\/strong\u003e, with more than half of the savings expected in \u003cstrong\u003e2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eSchrödinger, Inc. (SDGR) - VRIO Analysis: 9. Deep Scientific Support and Consulting Expertise\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Reduces onboarding friction and maximizes customer ROI, which drives high retention and software renewal rates. This is a key differentiator from pure code vendors.\u003c\/p\u003e\n\n\u003cp\u003eCustomer retention for customers with an Annual Contract Value (ACV) of at least $100,000 was 92% for the year ended December 31, 2023, and for customers with an ACV of at least $500,000 was 100% for the year ended December 31, 2022. The average tenure of the 10 largest software customers in 2023 was nearly 19 years.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate; while support exists everywhere, the depth of PhD-level application scientists is less common.\u003c\/p\u003e\n\n\u003cp\u003eThe drug discovery group is comprised of approximately 180 experts in protein science, biochemistry, biophysics, medicinal and computational chemistry, and discovery scientists with expertise in preclinical and early clinical development.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Moderate; requires maintaining a large, highly specialized, and expensive scientific workforce.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High; this team directly supports the high-margin software revenue stream.\u003c\/p\u003e\n\n\u003cp\u003eSoftware gross margin for Q3 2025 and Q3 2024 was 73%. Full-year 2024 Software Revenue was $180.4 million.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary; competitors can hire similar talent, but building the institutional knowledge takes time.\u003c\/p\u003e\n\n\u003cp\u003eThe financial performance related to the scientific support structure includes:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003ePeriod\/Date\u003c\/td\u003e\n\u003ctd\u003eAmount\/Rate\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSoftware Revenue\u003c\/td\u003e\n\u003ctd\u003eQ3 2025\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$40.9 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSoftware Revenue Growth (YoY)\u003c\/td\u003e\n\u003ctd\u003eQ3 2025 vs Q3 2024\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e28%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSoftware Gross Margin\u003c\/td\u003e\n\u003ctd\u003eQ3 2025 and Q3 2024\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e73%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D Expenses\u003c\/td\u003e\n\u003ctd\u003eQ3 2025\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$42.8 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D Expenses\u003c\/td\u003e\n\u003ctd\u003eQ3 2024\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$51 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eKey metrics demonstrating the success driven by the scientific expertise include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eCustomer retention rate for $\\ge$ $500,000 ACV customers in FY2024: \u003cstrong\u003e100%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eCustomer retention rate for $\\ge$ $100,000 ACV customers in FY2023: \u003cstrong\u003e92%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eNumber of customers with $\\ge$ $1 million ACV as of year-end 2024: \u003cstrong\u003e31\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eNumber of customers with $\\ge$ $5 million ACV as of year-end 2024: \u003cstrong\u003e8\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eTotal Annual Contract Value (ACV) increase by year-end 2024: \u003cstrong\u003e23.7%\u003c\/strong\u003e to \u003cstrong\u003e$190.8 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eFocus areas for operationalizing this expertise:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eMaking initial expert consultations seamless to mitigate churn risk associated with onboarding taking 14+ days.\u003c\/li\u003e\n\u003cli\u003eMaintaining the scientific workforce of approximately 180 multidisciplinary experts.\u003c\/li\u003e\n\u003cli\u003eSupporting the high-margin software revenue stream, which achieved a gross margin of 73% in Q3 2025.\u003c\/li\u003e\n\u003c\/ul\u003e\u003c\/h\u003e\u003c\/h\u003e\u003c\/h\u003e\u003c\/h\u003e\u003c\/h\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516247597205,"sku":"sdgr-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/sdgr-vrio-analysis.png?v=1740213381","url":"https:\/\/dcf-model.com\/pt\/products\/sdgr-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}